Piramal Pharma Limited (NSE:PPLPHARMA)
India
· Delayed Price · Currency is INR 151.40
-0.47 (-0.31%)
At close: Mar 9, 2026
Piramal Pharma Revenue
Piramal Pharma had revenue of 21.40B INR in the quarter ending December 31, 2025, a decrease of -2.92%. This brings the company's revenue in the last twelve months to 88.71B, down -0.87% year-over-year. In the fiscal year ending March 31, 2025, Piramal Pharma had annual revenue of 91.51B with 11.99% growth.
Revenue (ttm)
88.71B
Revenue Growth
-0.87%
P/S Ratio
2.27
Revenue / Employee
16.20M
Employees
5,476
Market Cap
201.04B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 91.51B | 9.80B | 11.99% |
| Mar 31, 2024 | 81.71B | 10.90B | 15.39% |
| Mar 31, 2023 | 70.82B | 3.47B | 5.16% |
| Mar 31, 2022 | 67.34B | 8.47B | 14.39% |
| Mar 31, 2021 | 58.87B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Wockhardt | 31.74B |
| Eris Lifesciences | 30.65B |
| NATCO Pharma | 45.63B |
| Emcure Pharmaceuticals | 88.50B |
| Gland Pharma | 61.13B |
| Alembic Pharmaceuticals | 72.67B |
| Alivus Life Sciences | 25.12B |
| Ajanta Pharma | 52.02B |